Abstract 472P
Background
Radiological part-solid nodules (PSNs) containing both solid and ground-glass opacity (GGO) component has lower incidence of nodal metastasis and better prognosis than radiological solid nodules. Previous studies demonstrated that risk of recurrence in GGO-predominant PSNs (0< consolidation-to-tumor ratio ≤0.5) was negligible, while recurrence was not rare in solid- predominant PSNs (0.5< consolidation-to-tumor ratio <1). However, the detailed recurrence patterns and the role of adjuvant therapy after recurrence remained unclear in solid-predominant PSNs.
Methods
Patients with cN0 solid-predominant PSNs (0.5< consolidation-to-tumor ratio <1) undergoing surgery from 2008 to 2015 were collected. The exclusion criteria were as follows: (a) adenocarcinoma in situ or minimally invasive adenocarcinoma, (b) history of other malignancy, (c) multiple primary lesions, and (d) positive resection margin. Median follow-up time was 77.0 months. The initial recurrence site and adjuvant treatment data were collected.
Results
This study included 443 solid-predominant PSNs. Postoperative recurrence was diagnosed in 88 patients (19.9%), including 38 (8.6%) distant, 26 (5.9%) locoregional, and 24 (5.4%) combined recurrences. Lymph node metastasis (P=0.011), lymphovascular invasion (P=0.001), and larger solid component size (P=0.007) were independent predictors of postoperative recurrence. Multivariate Cox regression identified older age (P=0.014, HR=1.044) and early recurrence (P<0.001, HR=4.046) as independent predictors of decreased survival in patients who experienced recurrence. EGFR mutation and ALK rearrangement were identified in 44 (50.0%) and 3 (3.4%) patients who experienced recurrence, respectively. Tyrosine kinase inhibitors demonstrated significant advantages over chemotherapy in patients who experienced recurrence. (median overall survival: 75 vs. 52 months, P=0.004).
Conclusions
Radiological solid-predominant PSNs comprise a heterogeneous population. Active follow-up and effective adjuvant treatment is warranted in patients with risk factors of recurrence. Patients with driver mutations can greatly benefit from targeted therapy if recurrence occurs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract